European Commission approves Livmarli for patients with Alagille syndrome


Sumary of European Commission approves Livmarli for patients with Alagille syndrome:

  • ALGS is a rare and devastating liver disease impacting 1 out of every 30,000 people globally, with no treatments to address the severe and unrelenting itch that some patients describe as being ‘set on fire’ The most burdensome symptom associated with ALGS, pruritus, can often govern to liver transplantation.
  • Peetz noted this approval follows positive study results from ‘more than 6 years of data’ which showed livmarli induced and sustained ‘statistically significant and clinically meaningful’ reductions in pruritis compared with placebo among a cohort of patients with ALGS-associated cholestatic pruritis.

Want to know more click here go to source.

From -

Close

Languages